Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Eli Lilly LLY has experienced significant growth in the past few years, particularly driven by the success of its popular ...

Gut‑hormone incretins (e.g., GLP‑1 agonists) are the fastest growing segment, forecast to expand at a 33.15% CAGR through ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk NVO announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has ...

The Semaglutide Market, valued at USD 28.43 Billion in 2024, is anticipated to reach USD 93.60 Billion by 2035, growing at a CAGR of 10.47%. Growth drivers include the rising prevalence of ...

The $160 billion fund behind Ozempic-maker Novo Nordisk A/S says President Donald Trump's tariff war has created so much economic ... very important market for all of our investments," he ...

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Novo Nordisk said on Monday the European drugs regulator will allow a label update for its diabetes drug Ozempic to include a ...